P. Martin

发表

Tamoxifen for early breast cancer: an overview of the randomised trials

Mike Clarke, Luc Bijnens, Michael Gnant, 1998, The Lancet.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Y Wang, Mike Clarke, Donald A. Berry, 2005, The Lancet.

Toxicity burden score: a novel approach to summarize multiple toxic effects.

Y K Cheung, J. Leonard, Y. Cheung, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

Terry L. Smith, R. Collins, L. Holmberg, 1998, Lancet.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Ivanov, Harris, R. Collins, 2005, The Lancet.

Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme.

K. Hoang-Xuan, J. Peragut, O. Chinot, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical experience with lenalidomide alone or in combination with rituximab in indolent B-cell and mantle cell lymphomas.

P. Martin, S. Schuster, B. Shah, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma

L. Kwak, S. Rosen, P. Martin, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma

B. Cheson, A. Hui, A. Di Bacco, 2014, Blood Cancer Journal.

New monoclonal antibodies for non-Hodgkin's lymphoma.

J. Leonard, R. Elstrom, P. Martin, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Immunotherapy with epratuzumab in B-cell non-Hodgkin’s lymphoma

D. Goldenberg, P. Martin, J. Leonard, 2009 .

Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies.

J. Leonard, S. Ely, S. Chen‐Kiang, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group.

N. Reguart, M. Provencio, P. Martin, 2020, Lung cancer.

Concomitant chemoradiotherapy followed, where feasible, by surgery for cancer of the esophagus.

B. Dubray, J. Douillard, P. Martin, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of chemotherapy dose-related factors on survival in breast cancer patients treated with adjuvant anthracycline-based chemotherapy.

I. Chirivella, A. Lluch, A. Bosch, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MAINTENANCE RITUXIMAB IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL IN MANTLE CELL LYMPHOMA PATIENTS RESPONDING TO INDUCTION THERAPY WITH BENDAMUSTINE + RITUXIMAB (BR)

C. Flowers, K. Blum, P. Martin, 2019, Hematological Oncology.

Extranodal testicular anaplastic versus plasmablastic plasma cell tumor: A rare case with diagnostic dilemma in a developing country

P. Martin, S. Hercules, A. Ramesh, 2011, Indian Journal of Medical and Paediatric Oncology.

Surveillance CT scans are a source of anxiety and fear of recurrence in long-term lymphoma survivors.

J. Leonard, M. Charlson, R. Elstrom, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

C. Meisner, N. Harbeck, G. von Minckwitz, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin’s lymphoma (NHL): CALGB 50803 (Alliance)

J. Leonard, B. Cheson, B. Pitcher, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy.

O. Chinot, D. Figarella-Branger, D. Braguer, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance).

J. Leonard, B. Cheson, B. Pitcher, 2017 .

OUTCOMES FOR PATIENTS WITH MANTLE CELL LYMPHOMA EXPERIENCING FRONTLINE TREATMENT FAILURE: A MULTICENTER RETROSPECTIVE STUDY

C. Flowers, K. Blum, P. Martin, 2019, Hematological Oncology.

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

C. Tournigand, M. Espié, B. Weber, 2019, The Lancet.

Durable responses with the antiangiogenic metronomic regimen RT-PEPC in elderly patients with recurrent mantle cell lymphoma (MCL).

P. Martin, R. Furman, M. Schuster, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.